key: cord-0077264-pc8iy51s
authors: Li, Minchao; Yuan, Yue; Li, Pingchao; Deng, Zhaomin; Wen, Ziyu; Wang, Haiying; Feng, Fengling; Zou, Huachun; Chen, Ling; Tang, Shixing; Sun, Caijun
title: Comparison of the Immunogenicity of HIV-1 CRF07_BC Gag Antigen With or Without a Seven Amino Acid Deletion in p6 Region
date: 2022-04-05
journal: Front Immunol
DOI: 10.3389/fimmu.2022.850719
sha: c55585f1a04b9a93412a1748f6d1892bc2506b6d
doc_id: 77264
cord_uid: pc8iy51s

HIV-1 CRF07_BC-p6Δ7, a strain with a seven amino acid deletion in the p6 region of the Gag protein, is becoming the dominant strain of HIV transmission among men who have sex with men (MSM) in China. Previous studies demonstrated that HIV-1 patients infected by CRF07_BC-p6Δ7 strain had lower viral load and slower disease progression than those patients infected with CRF07_BC wild-type strain. However, the underlying mechanism for this observation is not fully clarified yet. In this study, we constructed the recombinant DNA plasmid and adenovirus type 2 (Ad2) vector-based constructs to express the HIV-1 CRF07_BC Gag antigen with or without p6Δ7 mutation and then investigated their immunogenicity in mice. Our results showed that HIV-1 CRF07_BC Gag antigen with p6Δ7 mutation induced a comparable level of Gag-specific antibodies but stronger CD4(+) and CD8(+) T-cell immune responses than that of CRF07_BC Gag (07_BC-wt). Furthermore, we identified a series of T-cell epitopes, which induced strong T-cell immune response and cross-immunity with CRF01_AE Gag. These findings implied that the p6(Gag) protein with a seven amino acid deletion might enhance the Gag immunogenicity in particular cellular immunity, which provides valuable information to clarify the pathogenic mechanism of HIV-1 CRF07_BC-p6Δ7 and to develop precise vaccine strategies against HIV-1 infection.

The epidemic of HIV-1 infection remains a global health crisis. According to the report issued by the Joint United Nations Program on HIV/AIDS (UNAIDS), 37.7 million people were living with HIV-1 including 10.2 million untreated, 1.5 million new HIV-1 infections, and 680,000 AIDS-related deaths at the end of 2020. Although antiretroviral therapy (ART) can effectively control viral replication in AIDS patients, the withdrawal of ART will inevitably lead to a rapid rebound of plasma viremia because of the stable and long-lived latent virus reservoirs (1, 2) . Thus, HIV-1 patients have to receive life-long ART therapy. An effective HIV-1 vaccine is therefore considered the most cost-effective intervention to eventually terminate the HIV-1 spread. However, the extraordinary genetic diversity, latent viral reservoirs, and lack of the immune correlates of protection against HIV-1 infection are the major challenges for developing an effective HIV-1 vaccine. So far, hundreds of HIV-1 vaccine trials have been studied, including the AIDSVAX trial (protein subunit vaccine, aimed to produce the neutralizing antibodies), STEP trial (viral vectored-HIV vaccine, aimed to elicit T-cell immune responses), and RV144 trial (combined immunization with ALVAC-HIV/AIDSVAX, aimed to induce a balanced immunity with both humoral and cellular responses) (3, 4) . Among them, the RV144 trial remains the only one to demonstrate a positive signal with an estimated efficacy of 31.2% (5) . Therefore, it is of great significance to develop the next generation of HIV-1 prophylactic vaccine to confer better immune protection or therapeutic vaccines to achieve a functional cure.

Circulating recombinant form 07_BC strain (CRF07_BC) is a genotype of HIV-1 with a clade C backbone in which several Thailand variant fragments of clade B into structural and accessory genes were inserted (6) . CRF07_BC originated in Yunnan and spread rapidly in Western China and then nationwide (7) . Subsequently, HIV-1 CRF07_BC had caused an epidemic among Taiwan injection drug users in 2004 (8, 9) . Full-length genomic analysis of CRF07_BC revealed that there were some deletions (7-11 amino acids) in the p6 (Gag) and p6 (Pol) proteins (10) . Our previous study showed that the prevalence of 07_BC-p6D7 strain constantly increased and exceeded 90% in the men who have sex with men (MSM) population infected by HIV-1 CRF07_BC in China (11) , indicating that 07_BC-p6D7 is becoming the dominant strain among MSM in China. Notably, the deletion sequences YPX(n)L in the Gag p6 region mediated the interaction with ALG-2 interacting protein X (Alix) protein, which functions not only in multivesicular body (MVB) biogenesis but also in apoptosis, endocytosis, and cytokinesis pathways (12) . In addition, p6D7 mutation reduced the protease-mediated processing of Gag/Gag-Pol polyproteins and decreased the incorporation of Vpr protein in the virus particle, leading to a reduced viral load and replication, slower viral maturation processes, and an increased proportion of immature virus particles (13, 14) . These characteristics of CRF07_BC-p6D7 might be the consequence of co-adaption between the host and the virus. The lower viral load and slower disease progression seem to be beneficial to the host survival, but they also prolong the virus survival time, and the unapparent symptom before clinical diagnosis might also provide more opportunity to spread this strain among the population and thus poses a serious public health threat.

It is of note that the Gag protein is a well-known antigen to stimulate cellular responses to control HIV-1 replication and has thus been extensively studied as an ideal target for developing the HIV-1 vaccine. HIV-1-specific T cell responses play pivotal roles in controlling viral infection (15, 16) . The strong cellular response not only protected acute HIV-1 infection by reducing initial peak viremia to viral set point (17, 18) but also existed in long-term non-progressors with chronic HIV-1 infection (19, 20) . Moreover, HIV-1-specific T-cell immune responses induced by different HIV-1 proteins, especially the specific cytotoxic T lymphocyte (CTL) response against the Gag protein, could control HIV-1 replication to maintain a low steady-state viremia in several independent cohort studies (21) (22) (23) (24) . Considering that the Gag-specific T-cell immune responses can contribute to controlling the viral load and disease progression, we therefore speculate whether the p6D7 mutation in the Gag protein might change the Gag-specific immune responses and then affect the disease progression. We therefore address this critical issue in this study using 15-mer overlapping peptides spanning the entire sequence of the Gag protein to identify the specific T-cell epitopes through ELISpot as well as intracellular cytokine staining (ICS) assay.

The HIV-1 Gag protein sequences were obtained from the National Center for Biotechnology Information (NCBI) including HIV-1 CRF07_BC-p6D7 (GenBank: AHA50525.1) and CRF01_AE (GenBank: AFV34153.1). The Gag sequence was optimized according to the preferred codon usage of mammalian cells as previously described (25) and chemically synthesized by Invitrogen (Carlsbad, CA, USA). Subsequently, the CRF07_BC gag full length with the supplemental deletion of seven amino acids in the p6 region (07_BC-wt) was obtained using overlap extension PCR with two pairs of specific primers designed based on the CRF07_BC-p6D7 sequence (Primer: A1:5′ C T T A A G C T T A C C A T G G G C G C C , B 1 : 5 ′ C C C T C T A G A T T T A G G G C A G C A G G G G , A 2 : 5 ′ G T A C A G C T C CTTGTCAATGGGCTCCTGCTTCTGGGATGGGG, B2:5′ C C C A T T G A C A A G G A G C T G T A C C C C A T C A C CTCCCTGAAGTC). The codon-optimized Gag gene was then cloned into the pVAX-1 expression vector (Invitrogen) and adenovirus type 2 (Ad2) vector. Recombinant adenoviruses were generated using homologous recombination methods as our previous study described (26) .

In this study, a total of 121 of 15-mer peptides overlapping by 11 amino acid residues and spanning the gene sequence of 07_BC-wt were designed using the software PeptGen (http:// www.hiv.lanl.gov/content/sequence/PEPTGEN/peptgen.html) and synthesized (purity: >85%, GeneScript, China). The peptide pool was divided into 12 pools, each of which contained 10 peptides, and the last peptide pool contained 11 peptides (Supplementary Table 1 ). All of the peptides were dissolved in dimethyl sulfoxide (DMSO) at 0.4 mg/ml.

To confirm the expression of the target protein, human embryonic kidney (HEK) 293 cells in 6-well plates were transfected with pVAX-01AEgag, pVAX-07BCgag-p6D7, pVAX-07BCgag-wt, or pVAX-empty at 2 mg per well or infected with rAd2-01AEgag, rAd2-07BCgag-p6D7, rAd2-07BCgag-wt, or rAd2-empty at 0.2 TCID50 per well for 48 h at 37°C. Subsequently, cells were lysed, and the proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under denaturing and reducing conditions. Proteins were transferred to the polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA, USA). After being blocked for 1 h with 5% skim milk in Tris buffered saline with Tween-20 (TBST) the membrane was incubated overnight with a rabbit monoclonal anti-Gag antibody (Abcam, Cambridge, UK) and a mouse monoclonal anti-GAPDH antibody (Abcam) at 4°C. The membrane was washed and then incubated with horseradish peroxidase-conjugated anti-rabbit IgG antibody or anti-mouse IgG antibody at a 1:5,000 dilution (Abcam) for 2 h. Finally, the membranes were developed with a chemiluminescent horseradish peroxidase (HRP) substrate (Invitrogen). The expression of GAPDH was also examined in parallel as an internal control.

Female BALB/c mice aged 6-8 weeks were randomly allocated into five groups (n = 10 per group). Group 1 received 100 ml of PBS per mouse served as the negative control. Each mouse of groups 2 to 5 was intramuscularly injected with 50 mg of the DNA plasmid dissolved in 100 ml of PBS in the right quadriceps of the leg at weeks 0 and 2 and then boosted intramuscularly with 1 × 10 9 vp of the corresponding adenoviral vector vaccine in the right quadriceps of the leg at weeks 4. At weeks 3 and 6, five mice in each group were anesthetized with inhaled isoflurane and sacrificed by cervical dislocation. Then, the splenocytes were obtained and subjected to subsequent immunological analyses.

IFN-g ELISpot assay was performed to detect cellular immune response using freshly isolated mouse splenic lymphocytes as previously described (25) . Briefly, 96-well plates (Merck Millipore, Burlington, MA, USA) were washed and coated with purified rat anti-mouse IFN-g monoclonal antibody U-CyTech, Netherlands at 4°C overnight. Mouse splenic lymphocytes were isolated using mouse lymphocyte separation solution (Dakewe Biotech Co., Ltd., Shenzhen, China) and seeded in the plates at 3 × 10 5 per well. Then each group was incubated with the peptide pool at 4 mg/ml, while DMSO served as a negative control. After incubation for 24 h, the plates were incubated with biotinylated detection antibodies (U-CyTech) and developed with alkaline phosphatase-conjugated streptavidin (BD Biosciences, San Jose, CA, USA) and NBT/BCIP reagent (Thermo Fisher Scientific, Waltham, MA, USA). Finally, the spots were counted with an ELISpot reader (Bioreader 4000, BIO-SYS, Karben, Germany).

The antigen-specific cytokine secreted by lymphocytes was also detected by ICS assay as previously described (27) . Briefly, mouse splenic lymphocytes were seeded in the 96-well plates at 2 × 10 6 per well and incubated with the peptide pool at 4 mg/ml for 2 h at 37°C. Then brefeldin A (BD Biosciences) was added and incubated for 16 h at 37°C. The cells were harvested and stained with CD3-PerCP-Cy-5.5, CD4-APC, and CD8-PE (BD Biosciences) for 30 min protected from light; then added with cytofix/cytoperm (BD Biosciences) to permeabilize for 30 min protected from light; and stained with IFN-g-FITC, IL-2-APC-Cy7, and TNF-a-PE-Cy7 (BD Biosciences) for 1 h protected from light at 4°C. Samples were analyzed using the FACSAria instrument with FlowJo software (version 7.6).

To identify the potential CTL epitopes, the single 15-mer peptide in the peptide pools of the 07BC Gag protein was analyzed using the NetMHCpan-4.0 EL 4.0 algorithm with a size range of 8-to 11-mers amino acid (28, 29) . The most frequent major histocompatibility complex (MHC) class I alleles in BALB/c mice, including H-2-Dd, H-2-Kd, and H-2-Ld, were selected as a model to analyze the potential CTL epitopes. The epitope was determined based on the Percentile Rank, which was lower than 0.5 (most likely to be considered as high-affinity epitopes). In addition, 01AE was aligned with 07BC-p6D7 using NCBI blast software (Supplementary Figure 1) and predicted CTL epitope through NetMHCpan-4.0 EL 4.0 algorithm.

Flow cytometric data were analyzed using FlowJo version 7.6. Statistical analyses and graphical presentations were conducted with GraphPad Prism version 8.0. One-way ANOVA was used for the comparison among multiple (>2) groups, and a two-tailed unpaired Student's t-test was used for comparison between two groups (07BC-p6D7 and 07BC-wt). Data were expressed as mean ± SEM, and p-values of less than 0.05 were deemed statistically significant. *p < 0.05; **p < 0.01; ***p < 0.001; NS, no significance.

As described in the Materials and Methods, we successfully obtained the genes of CRF07_BC-p6D7, CRF07_BC gag full length (07_BC-wt), and CRF01_AEgag. To assess their immunogenicity, we constructed the recombinant pVAX-1 vector and adenovirus type 2 vector carrying various Gag genes under the control of the CMV promoter ( Figure 1A) . The Ad2 vector with deletion of E1 and E3 genes was replicationdefective, and Gag gene was inserted into the E1 region. Then recombinant Ad2 was rescued and propagated in HEK293 cells, which can provide E1 protein to support the replication of this E1-deleted virus. Western blotting results showed that both the DNA constructs and Ad2 constructs appropriately expressed the corresponding Gag protein with expected molecular weight (55 kDa) ( Figure 1B) .

To investigate the immunogenicity of the Gag protein with or without p6D7 mutation, 6-to 8-week-old female BALB/c mice were immunized as shown in Figure 2A , and then the antigenspecific immune responses were evaluated. Previous studies demonstrated that the Gag-specific T-cell immune response, but not Gag-specific antibody, was associated with lower viremia and better HIV-1 control (21, 22) . Since there was a comparable level of Gag-specific antibodies in both the 07BCgag-p6D7 group and 07BCgag-wt group, we focused on the Gagspecific T-cell immune response in the following study. In our study, the peptide pool covering the full length of the Gag protein was divided into 12 sub-pools (pool 1-pool 12) to stimulate mouse spleen lymphocytes ( Figure 2B ). After immunization with recombinant DNA and Ad2 vectored constructs, the peptide pools covering different regions of the Gag protein elicited T-cell immune responses with different intensities ( Figure 2C ). There were obvious T-cell immune responses induced by pool 2, pool 4, pool 8, pool 11, and pool 12, but not for the remaining sub-peptide pools. Among them, the immune responses elicited by the stimulation of peptide pool 2, pool 4, and pool 8, which are located at the p17 and p24 regions of the Gag protein, were stronger than those of pool 11 and pool 12, which are located at the p7 and p6 regions of the Gag protein. Of note, there were stronger T-cell immune responses in the 07_BC-p6D7 group when compared with the 07_BC-wt group, suggesting that the seven amino acid deletion in the p6 region might mainly affect the immunogenicity of Tcell epitopes in the Gag protein.

We then mapped the T-cell epitopes in the mice immunized with different vaccine constructs. IFN-g ELISpot assay was performed to identify the vaccine-induced T-cell response towards each peptide in pool 2, pool 4, and pool 8 by setting the cutoff value of 50 spot-forming cells (SFCs)/10 6 cells as a positive response (30) . After the background was subtracted, the median value is shown in Figure 3A , and a series of T-cell epitopes were identified ( Table 1) . After the identification of overall T-cell responses, the positive responses against specific peptide pools were then characterized by CD4 + or CD8 + T-cell subsets for ICS assay ( Figure 3B and Supplementary Figure 2) . The frequency of IFN-g-positive CD4 + and CD8 + T cells is shown in Table 1 . In our study, twelve peptides could stimulate a positive CD8 + T-cell response, and three peptides could stimulate a positive CD4 + Tcell response. Except for peptide 73, the most positive peptides confirmed by IFN-g ELISpot assay could also be recognized by the ICS assay of CD4 + or CD8 + T-cell subsets.

We further constructed the epitope mapping to analyze the breadth of the cellular response after vaccination ( Figure 3C ).

Of note, although the overlapping peptide pool was constructed based on the sequence of the 07BC Gag protein, it also stimulated the splenocytes from 01AE-immunized mice to produce high levels of IFN-g secretion. Therefore, we aligned 01AE (GenBank: AFV34153.1) and 07BC-p6D7 (GenBank: AHA50525.1) sequences using NCBI blast software (Supplementary Figure 1) and found that the similarity of amino acid sequences between 01AE and 07BC-p6D7 was 82%. To identify the cross-reactive T-cell epitopes, the single 15-mer peptide in the peptide pools of the 07BC Gag protein was analyzed using the NetMHCpan-4.0 EL 4.0 algorithm with a size range of 8-to 11mer amino acid. As shown in Table 2 , we predicted 6 crossreactive CTL epitopes, which were most likely to be high-affinity epitopes. Furthermore, these cross-reactive CTL epitopes were conserved and maintained the recognition of CD8 + T cells restricted by different MHC-I molecules even with a single amino acid substitution. Consistent with our prediction, peptide 36 (HQPISPRTLNAWVKV) contains two epitopes and thus effectively induced more than 300 SFCs/10 6 in IFN-g ELISpot assay that targets different MHC-I molecules, suggesting that this peptide might induce extensive cross-reactive Gagspecific T-cell responses for effective HIV-1 control.

To further study the poly-functionality of T-cell populations after immunization with various Gag modalities, we performed the multi-parameter ICS assay to assess the Gag-specific cellular immunity. The frequency of CD4 + T-cell subsets producing one cytokine (IFN-g, TNF-a, and IL-2) or more cytokines (IFN-g + / IL-2 + , IFN-g + /TNF-a + , and IL-2 + /TNF-a + ) was analyzed using the exclusive gating strategy ( Figure 4A ). Statistical analysis demonstrated that the frequency of CD4 + T cells secreting one cytokine or dual cytokines in the 07BC-p6D7-immunized mice was significantly higher than that of the 07_BC-wt group, especially in response to the stimulation of pool 2 and pool 8 peptides (Figures 4B, C) . In addition, a similar observation was also found in the CD8 + T cells secreting one cytokine or dual cytokines ( Figures 4D-F ).

In this study, we evaluated the immunogenicity of the HIV-1 CRF07_BC Gag antigen with or without a seven amino acid deletion in the p6 region in mice. Our results demonstrated that CRF07_BC-p6D7 induced a stronger T-cell immune response than CRF07_BC-wt. The difference between the two sequences is the seven amino acids in the Gag p6 region, which are critical for binding with Alix protein. Mutations at the Alix-binding site of the p6 region led to impaired HIV-1 replication and the decreased efficiency of viral budding in various cell types (12) . A previous study revealed that the expression of Galectin-3 was upregulated in response to HIV-1 CRF07_BC infection (31) , and the endogenous Galectin-3 facilitated the binding of Alix-Gag p6 complex to promote HIV-1 budding (32). However, this promoting effect could be disrupted because of the seven amino acid deletion in the Gag p6 region (33) . Thus, p6D7 might play an important role in controlling the lower viral load and slower disease progression. In addition, Galectin-3 negatively regulates the adhesion between T cell and antigen-presenting cells (APCs) by destabilizing the immunological synapse, and the possible mechanism is through modulating Alix's function to downregulate the T-cell function (34) . This is consistent with our results that 07BC Gag with a seven amino acid deletion induced higher magnitude IFN-g in ELISpot assay and higher frequency of Gag-specific (p17 and p24) cytokine including IFN-g, IL-2, and TNF-a, indicating that the seven amino acid deletion in the p6 region might promote the immunogenicity of Gag antigen by disrupting the interactions between Galectin-3 and Alix-Gag p6 complex. Since it is well known that the enhancement of Gagspecific T-cell immune response can contribute to controlling the Background-subtracted IFN-g SFC/10 6 splenocytes. c Background-subtracted frequency of responding CD3 + CD4 + IFN-g cells as percentage of all CD3 + CD4 + splenocytes. d Background-subtracted frequency of responding CD3 + CD8 + IFN-g cells as percentage of all CD3 + CD8 + splenocytes. viral load and disease progression, our findings provide a new explanation for the abovementioned observation.

The cross-recognition of viral epitopes by CD8 + T cells is related to viral control during HIV-1 infection and is thus vital to develop a vaccine strategy that can elicit cross-reactive T-cell responses to target the conserved regions of the viral antigens, which is an important requirement for an effective vaccine against HIV-1 variants (35, 36) . In our study, we also identified seven 15-mer peptides, which can induce a high magnitude of IFN-g secretion in ELISpot assay, and further predicted six CD8 + T-cell epitopes located at the conserved p17 and p24 region of the 01AE Gag and the 07BC Gag, indicating that there might be a strong cross-reactive immune response between the 01AE Gag antigen and the 07BC Gag antigen. Among them, peptide 36 (HQPISPRTLNAWVKV) | Assessment of Gag-specific cellular immunity elicited by Ad2 vaccine through intracellular cytokine staining (ICS) assay. The ability of polyfunctional CD4 + and CD8 + T-cell populations from immunized mice to secrete IFN-g, TNF-a, and IL-2 cytokines in response to Gag peptide pools stimulation was assessed. The background-subtracted median responses (n = 5) in BALB/c mice following vaccination are shown. Gating strategy for flow cytometric scatter plots to analyze the frequency of the single or multiple cytokine(s)-positive CD4 + (A) or CD8 + (D) T cells. Frequencies of CD4 + (B) or CD8 + (E) T cells secrete IFN-g, TNF-a, and IL-2 cytokines specific to various Gag antigens after adenoviral-based immunization. Further analysis was performed to show subpopulations of double cytokinessecreting CD4 + T cells (C) or CD8 + T cells (F). Data were expressed as mean ± SEM, and p-values of less than 0.05 were deemed statistically significant.*p < 0.05; **p < 0.01; ***p < 0.001; NS, no significance. induced a robust T-cell immunity, and further analysis demonstrated that it contained two CTL epitopes with the potential to target different MHC-I molecules. HIV-1 CRF07_ BC was a recombinant virus of the B′ and C subtypes, which probably shared 50% CTL epitopes in Gag and reverse transcriptase (RT) with prototype B strain (6) . Interestingly, the cross-reactive T-cell responses in HIV CRF01_AE and B′ had been observed (37) . This evidence supported that there were cross-reactive T-cell responses between 01AE and 07BC, which is consistent with our findings.

To our best knowledge, this is the first study to investigate the immunogenicity of HIV-1 CRF07_BC with or without seven amino acid deletions in the p6 region of the Gag protein, and we found that the seven amino acid deletion in the p6 region contributed to the increased CD4 + and CD8 + T immune response against Gag antigen. These data should be helpful to clarify the mechanism why HIV-1 CRF07_BC-p6D7 patients have a lower viral load and slower disease progression than other patients. However, further study is needed to distinguish the clinical course and immunological response in patients infected with CRF07_BC-p6D7 compared to CRF07_BC strains. In addition, our findings will also provide insights for the development of Gag-based vaccine strategies against HIV-1 infection.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

All animal experiments were conducted in the Animal Experimental Center of the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. This experimental protocol was approved by the Institutional Animal Care and Use Committee of Guangzhou Institute of Biomedicine and Health (Aprroved number:2020053; Date of acceptance: April 3, 2020; Duration: Four months).

Arsenic Trioxide Impacts Viral Latency and Delays Viral Rebound After Termination of ART in Chronically SIV-Infected Macaques

Exacerbated AIDS Progression by PD-1 Blockade During Therapeutic Vaccination in Chronically SIV-Infected Rhesus Macaques After ART Treatment Interruption

Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions

A Zigzag But Upward Way to Develop an HIV-1 Vaccine. Vaccines (Basel) (2020)

Vaccination With ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

Characterization of a Virtually Full-Length Human Immunodeficiency Virus Type 1 Genome of a Prevalent Intersubtype (C/B') Recombinant Strain in China

On-Going Generation of Multiple Forms of HIV-1 Intersubtype Recombinants in the Yunnan Province of China

Molecular Epidemiology of HIV Type 1 Subtypes in Taiwan: Outbreak of HIV Type 1 CRF07_BC Infection in Intravenous Drug Users

An Epidemic of HIV Type I CRF07_BC Infection Among Injection Drug Users in Taiwan

Molecular Epidemiology of HIV-1 Infection and Full-Length Genomic Analysis of

Circulating Recombinant Form 07_BC Strains From Injection Drug Users in Taiwan

HIV-1 CRF07_BC With a Seven Amino Acid Deletion in the Gag P6 Region Dominates in HIV-1-Infected Men Who Have Sex With Men in China

Functional Role of Alix in HIV-1 Replication

Slow Immunological Progression in HIV-1 CRF07_BC-Infected Injecting Drug Users

Patients Infected With CRF07_BC Have Significantly Lower Viral Loads Than Patients With HIV-1 Subtype B: Mechanism and Impact on Disease Progression

The First T Cell Response to Transmitted/Founder Virus Contributes to the Control of Acute Viremia in HIV-1 Infection

Broad and Persistent Gag-Specific CD8+ T-Cell Responses are Associated With Viral Control But Rarely Drive Viral Escape During Primary HIV-1

Temporal Association of Cellular Immune Responses With the Initial Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Syndrome

CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection

HIV Nonprogressors Preferentially Maintain Highly Functional HIV-Specific CD8+ T Cells

The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates With Residual Viral Loads in HIV Elite Controllers

CD8 T-Cell Recognition of Multiple Epitopes Within Specific Gag Regions Is Associated With Maintenance of a Low Steady-State Viremia in Human Immunodeficiency Virus Type 1-Seropositive Patients

CD8+ T-Cell Responses to Different HIV Proteins Have Discordant Associations With Viral Load

Mucosal Priming With a Replicating-Vaccinia Virus-Based Vaccine Elicits Protective Immunity to Simian Immunodeficiency Virus Challenge in Rhesus Monkeys

Immune Protection of SIV Challenge by PD-1 Blockade During Vaccination in Rhesus Monkeys

Induction of Balance and Breadth in the Immune Response Is Beneficial for the Control of SIVmac239 Replication in Rhesus Monkeys

Circumventing Antivector Immunity by Using Adenovirus-Infected Blood Cells for Repeated Application of Adenovirus-Vectored Vaccines: Proof of Concept in Rhesus Macaques

Regulating Innate and Adaptive Immunity for Controlling SIV Infection by 25-Hydroxycholesterol

NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

Rational Design of a Pan-Coronavirus Vaccine Based on Conserved CTL Epitopes

Effect of Epitope Variant Co-Delivery on the Depth of CD8 T Cell Responses Induced by HIV-1 Conserved Mosaic Vaccines

The Examination of Viral Characteristics of HIV-1 CRF07_BC and Its Potential Interaction With Extracellular Galectin-3. Pathogens (2020)

Promotes HIV-1 Budding via Association With Alix and Gag P6

Amino Acid Deletions in P6(Gag) Domain of HIV-1 CRF07_BC Ameliorate Galectin-3

Mediated Enhancement in Viral Budding

Galectin-3 Negatively Regulates TCR-Mediated CD4+ T-Cell Activation at the Immunological Synapse

Mapping HIV-1 Vaccine Induced T-Cell Responses: Bias Towards Less-Conserved Regions and Potential Impact on Vaccine Efficacy in the Step Study

Cross-Reactive CD8 T-Cell Responses Elicited by Adenovirus Type 5-Based HIV-1 Vaccines Contributed to Early Viral Evolution in Vaccine Recipients Who Became Infected

Cross-Reactive T Cell Responses in HIV CRF01_AE and B'-Infected Intravenous Drug Users: Implications for Superinfection and Vaccines

We would like to thank all colleagues for their technical assistance in the animal experiments.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.